Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Archived from the original on 2009-03-20
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
If the vial needs to be out of the refrigerator temporarily for administration, brief periods at room temperature are acceptable
If you have specific health concerns, please speak with your GP
Significant results emerge after 8-12 weeks at therapeutic doses, not within the first seven days
US$ 28.06
US$ 27.24
US$ 26.60
